Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, has announced progress in its clinical study involving NB1, a product that combines recombinant human protein NELL-1 (rhNELL-1) with demineralized bone matrix (DBM). The company expects to complete enrollment in its first-in-human pilot study by the end of the year, despite a slower-than-anticipated start. This study is assessing the effectiveness of two concentrations of NB1 compared to an autograft control in up to 30 subjects, focusing on fusion success at 12 and 24 months post-surgery and changes from baseline in the Oswestry Disability Index. Bone Biologics plans to provide an interim update once all patients have reached a six-month follow-up. The company is also working on product improvements, including extending the protein's shelf life to 24 months and developing a more robust potency assay. These efforts are part of Bone Biologics' strategic plan to advance its clinical development program, with further updates expected as the study progresses.